Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Starting soon · Phase 2
Conditions studied: Duchenne Muscular Dystrophy (DMD)
In brief
This is a study of investigational medicines ENTR-601-44 and ENTR-601-45 designed to evaluate the long-term safety and tolerability of study drugs in participants with Duchenne muscular dystrophy (DMD). The investigational medicines are currently being investigated in multiple ascending dose parent studies. After participants complete their respective parent study, there is a need to understand the effects of long-term administration of ENTR-601-44 and ENTR-601-45. Participants enrolling in this study will begin this long-term extension (LTE) study at the dose level they received upon completion of the parent study with possible dose escalation in the LTE study based on emerging safety and efficacy data from the parent studies. Participants will: * Receive study treatment in the form of multiple intravenous (IV) infusions (slow injections) into a vein over the course of several weeks * Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, and excersice tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a results of the study drug. Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.
Key facts
- Study ID
- NCT07682129
- Run by
- Entrada Therapeutics, Inc.
- People needed
- 80
- Starts
- 2026-08-01
- Expected to finish
- 2032-03-01
- Last updated by the study team
- 2026-07-02
Who can join
Age: 4 and older, up to 20. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Willing and able to provide consent (if at age of majority) or assent (if a minor)
- Participant completed clinical study ENTR-601-44-201 or ENTR-601-45-201
- Males who are sexually active with a female partner of childbearing potential must agree to use condoms during sexual intercourse
You may not qualify if…
- Any change from the applicable parent study eligibility criteria, including safety events during the parent study, that in the opinion of the investigator in consultation with the medical monitor and/or sponsor designee precludes safe use of study drug
- Participant has a condition or circumstance that in the view of the investigator places the subject at high risk of poor treatment compliance or for not completing the study
Where it is running
- University Hospital Gent — Ghent, Belgium
- UZ Leuven — Leuven, Belgium
- Centre Hospitalier Régional de la Citadelle — Liège, Belgium
- IRCCS Ospedale San Raffaele — Milan, Italy
- Fondazione Serena Onlus - Centro Clinico NeMO Milano — Milan, Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore — Roma, Italy
- Ospedale Pediatrico Bambino Gesu — Rome, Italy
- Leids Universitair Medisch Centrum — Leiden, Netherlands
- Stichting Radboud Universitair Medisch Centrum — Nijmegen, Netherlands
- Hospital Universitario Vall d'Hebron — Barcelona, Spain
- Hospital Sant Joan de Deu — Barcelona, Spain
- Leeds General Infirmary — Leeds, United Kingdom
- Alder Hey Children's NHS Foundation Trust — Liverpool, United Kingdom
- Great Ormond Street Hospital for Children — London, United Kingdom
- Royal Manchester Children's Hospital — Manchester, United Kingdom
- Freeman Hospital — Newcastle upon Tyne, United Kingdom
- Oxford University Hospitals NHS Foundation Trust — Oxford, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.